Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Zevra Therapeutics Inc.

The latest update is out from Zevra Therapeutics ( ($ZVRA) ). On November 20, 2025, Zevra Therapeutics announced that its Chief Financial Officer, ...

Zevra Therapeutics CFO Resignation Announced

Zevra Therapeutics, Inc. ( ($ZVRA) ) has released its Q3 earnings. Here is a breakdown of the information Zevra Therapeutics, Inc. presented to its...

Zevra Therapeutics Reports Strong Q3 2025 Revenue Growth

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zevra Therapeutics (ZVRA – Research Report) and Tyra...

Market Cap	$497.67M	P/E Ratio	N/A
52W High	$13.16	52W Low	$6.19
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-2.6%	52W Position	34.6%
Overall Score	35	Value Score	60
Quality Score	--	Technical Score	10

EPS Current Est	$-0.02	EPS Next Est	$0.51
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ZVRA	$8.60	-4.97%	3.34M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ZVRA	$8.60	-5.0%	3.34M
3
4
5
6

ZVRA

ZVRA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Zevra Therapeutics Inc. Data in Excel

Get Zevra Therapeutics Inc. Data in Excel